Follow The Filings

HUMA Humacyte

Humacyte earnings company data as of 11:21 PM ET 11/17

  • 1 of 1 EPS beats

History

1 period, newest first. Each row shows EPS above revenue.

Period Date Metric Estimate Actual Result
FY2026 Q3 10 Nov EPS -0.08 -0.06 Beat
Rev $770.0K $1.0M Beat

Insider trades

Open-market buys and sales by HUMA's executives, directors and 10% owners in the last 12 months, from their Form 4s

All HUMA insider trades
  • $90K bought by 3 insiders
  • None no sales outside a trading plan
  • None no planned (10b5-1) sales
  1. Keith Anthony Jones Director
    Buy
    $5,620 10,000 shares at $0.5600 +25% to stake
    Traded Sep 14 Filed Sep 15
  2. Keith Anthony Jones Director
    Buy
    $6,930 10,000 shares at $0.6900 +33% to stake
    Traded Aug 20 Filed Aug 21
  3. Keith Anthony Jones Director
    Buy
    $18K 30,000 shares at $0.5900 New stake
    Traded Aug 17 Filed Aug 19
  4. Michael T. Constantino Director
    Buy
    $9,840 11,000 shares at $0.8900 +33% to stake
    Traded May 18 Filed May 20
  5. Kathleen Sebelius Director
    Buy
    $50K 56,818 shares at $0.8800 +62% to stake
    Traded May 19 Filed May 20

Also filed in the last 12 months, not counted as buying or selling: 2 sales to cover taxes.

SEC filings

Recent issuer filings from EDGAR, 20 shown.

Filed Form Detail Links
10-Q
8-K 2.02,9.01
8-K 5.02,7.01,9.01
SCHEDULE 13D/A —
8-K 2.02,9.01
10-Q
8-K 3.01
SCHEDULE 13G/A —
SCHEDULE 13D/A —
SCHEDULE 13G —
SCHEDULE 13D/A —
424B5
8-K 1.01,7.01,9.01
8-K 8.01,9.01
424B5
8-K 5.03,5.07,9.01
8-K 8.01
10-Q
8-K 3.01
DEF 14A

Estimates are consensus figures; SEC filings remain the official record. Not investment advice.

Further reading

As an Amazon Associate, FollowTheFilings earns from qualifying purchases.

More on the shelf